

23 September 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

Partnership with University of Strathclyde's CMAC National Facility

Collaboration combines N4 Pharma's innovative Nuvec® delivery platform with CMAC's world-class expertise to accelerate development and broaden therapeutic applications

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce a collaboration with CMAC, based at the University of Strathclyde in Glasgow.

CMAC is a leading international manufacturing research centre with a unique configuration of academic research, applied projects and pre-competitive programmes. Working with industry partners, academic institutions and innovation collaborators, CMAC's mission is to transform medicine development, manufacture and supply.

This collaboration brings together the expertise of Professor Yvonne Perrie, MBE, Head of the Strathclyde Institute of Pharmacy and Biomedical Sciences, alongside CMAC's National Facility team and N4 Pharma's scientific experts. The collaboration will focus on advancing the Nuvec® platform towards clinical readiness and characterising additional dual-loaded Nuvec® preclinical candidates, both *in vitro* and *in vivo*.

Professor Perrie is an internationally recognised authority in drug delivery, RNA vaccines and nanomedicine manufacturing, combining academic leadership, regulatory expertise and extensive industry collaboration. She began her career with Lipoxen Technologies Ltd, developing liposomal drug delivery platforms before moving into academia, where she has built a leading research portfolio in advanced drug and vaccine delivery. She has published more than 150 papers, is an inventor on multiple patents and serves on the Scientific Advisory Board of Quotient Sciences. Professor Perrie is also a Commissioner on the UK's Commission on Human Medicines and has advised the MHRA, WHO and other international regulators. In 2024, she was awarded an MBE for services to pharmaceutical innovation and regulation.

Her work with industry partners is extensive. With AstraZeneca, she has led projects on lipid nanoparticle characterisation and advanced analytics. With GSK Vaccines Siena, she directed studies on cationic lipid nanoparticles for self-amplifying RNA vaccines and on how nanoparticle design influences vaccine potency. With Pfizer, she has collaborated through the CPI consortium on microfluidics and the Medicines Manufacturing Innovation Centre, advancing innovation in nanomedicine manufacturing.

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

"We are delighted to partner with the University of Strathclyde and CMAC's National Facility. This collaboration builds upon excellent progress in our own programmes over the past few months and represents an important step in strengthening the commercial data package for Nuvec®, giving us access to world-class expertise and facilities to accelerate its development.

"Working with Professor Perrie and the CMAC world-class scientists enhances our ability to characterise Nuvec® in depth, showcase its unique benefits and explore its broader therapeutic applications. These efforts bring us closer to our goal of positioning Nuvec® as a leading gene delivery platform for nucleic acid therapies, supporting both our internal pipeline and future licensing opportunities."

Professor Yvonne Perrie, MBE, added:

"We are excited to collaborate with N4 Pharma on the continued development of the Nuvec® platform. Our work at CMAC's National Facility is focused on advancing innovation in drug delivery and pharmaceutical manufacturing. Partnering with N4 Pharma provides an excellent opportunity to apply our expertise in RNA vaccines and nanomedicine manufacturing to help accelerate the Nuvec® programme towards clinical readiness and broaden its potential applications."

Massimo Bresciani, Industry Director of CMAC, commented:

"This project demonstrates the strength of industry-academic partnerships in accelerating medicines manufacturing. By combining N4 Pharma's innovative delivery platform with CMAC's technical expertise, we aim to unlock new possibilities in RNA therapeutics."

- Ends -

For more information please contact:

N4 Pharma plc

Nigel Theobald, CEO
Luke Cairns, Executive Director

Via N4 Pharma Investor Hub:
investors.n4pharma.com

Submit your questions directly to the management team via
the N4 Pharma Investor Hub

<https://n4pharma.com/link/yEMX3y>

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate
Broking)

Tel: +44 (0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker
Andy Thacker
James Pope

Tel: +44 (0)20 3657 0050

Northstar Communications Limited

Investor Relations
Sarah Hollins

Tel: +44 (0)113 730 3896

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

For further information on the Company visit www.n4pharma.com or sign up at <https://investors.n4pharma.com/auth/signup>.

About CMAC

CMAC is an internationally leading medicines manufacturing research centre with a unique configuration of academic research, applied and pre-competitive programmes.

Working in partnership with large pharma, technology providers, academic and innovation partners, CMAC's goal is to transform medicines development, manufacture and supply and further grow its pipeline of world-class multi-disciplinary collaborative research.

The centre's portfolio currently includes the Made Smarter Innovation: Digital Medicines Manufacturing Research Centre (DM²), EPSRC international Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) collaboration, UKRPIF supported Net Zero Pilot and CMAC Data Lab, EPSRC CDT Cyber-physical Systems for Medicines Manufacturing (CEDAR), and the EPSRC MediForge Hub, along with training and translation projects within a world-class facility.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPKBBDBKDBC